|
271 Companies |
|
374 Products |
|
374 Products |
|
160 Mechanisms of Action |
|
34 Trials |
|
5514 News |
|
| «12...8889909192939495969798...110111» |
- veliparib (ABT-888) / AbbVie
Enrollment closed, Combination therapy, BRCA Biomarker, PARP Biomarker, Metastases: Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer (clinicaltrials.gov) - Mar 6, 2013
P1, N=107, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting
- Trial completion, HEOR: Psychosocial Support for African-American, Latina-American, or European-American Cervical Cancer Survivors (clinicaltrials.gov) - Mar 6, 2013
P=N/A, N=340, Completed, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting Recruiting --> Completed
- Enrollment closed: Study of Post Operative Pain in Endometrial Cancer Robotic Versus Laparotomy (clinicaltrials.gov) - Mar 4, 2013
P=N/A, N=160, Active, not recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
Recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| estradiol valerate / Generic mfg.
Enrollment closed: A Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis (clinicaltrials.gov) - Mar 4, 2013
P3, N=90, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- KHK 2866 / Kyowa Kirin
Trial termination, Combination therapy, Monotherapy, Metastases: Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer (clinicaltrials.gov) - Mar 4, 2013
P1, N=22, Terminated, Sponsor: Kyowa Hakko Kirin Pharma, Inc.
Recruiting --> Active, not recruiting Suspended --> Terminated; The study was stopped due to the inability to determine an acceptable dose with the potential for further study
- KHK 2866 / Kyowa Kirin
Enrollment change, Combination therapy, Monotherapy, Metastases: Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer (clinicaltrials.gov) - Mar 4, 2013
P1, N=22, Terminated, Sponsor: Kyowa Hakko Kirin Pharma, Inc.
Suspended --> Terminated; The study was stopped due to the inability to determine an acceptable dose with the potential for further study N=123 --> 22
- New P1 trial: Phase I Pilot Study to Evaluate the Prognostic Value of Perfusion CT for Primary Cervical Cancer (clinicaltrials.gov) - Mar 4, 2013
P1, N=20, Suspended, Sponsor: Stanford University
- |||| Vynfinit (vintafolide) / Novartis
Trial completion, Combination therapy: PRECEDENT: Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04) (clinicaltrials.gov) - Mar 4, 2013
P2, N=162, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=123 --> 22 Active, not recruiting --> Completed
- Trial termination: Belfort Dildy- Obstetrical Tamponade System Post-Marketing Surveillance Program (clinicaltrials.gov) - Mar 3, 2013
P=N/A, N=300, Terminated, Sponsor: Glenveigh Medical
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Study discontinued following 57 subjects enrolled over 2 years
- Trial completion: Human Papillomavirus in Menstrual Blood (clinicaltrials.gov) - Mar 3, 2013
P=N/A, N=19, Completed, Sponsor: Seoul National University Hospital
Active, not recruiting --> Terminated; Study discontinued following 57 subjects enrolled over 2 years Recruiting --> Completed
- || Enrollment closed: A Phase IV, Prospective, Observational, Open Label, Single Centre Cohort Trial to be Conducted in Norway During One Year to Assess the Cumulative Pregnancy Rate in a New Series of In-vitro Fertilization (IVF) Treatment Cycles Following Three or More Previous IVF Treatment Cycles Without Live Birth (clinicaltrials.gov) - Mar 3, 2013
P=N/A, N=166, Active, not recruiting, Sponsor: Merck KGaA
Recruiting --> Completed Recruiting --> Active, not recruiting
- alvocidib (DSP-2033) / Sumitomo Pharma
Enrollment closed: Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors (clinicaltrials.gov) - Mar 3, 2013
P2, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| sorafenib / Generic mfg.
Trial completion, Metastases: Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer (clinicaltrials.gov) - Feb 28, 2013
P2, N=246, Completed, Sponsor: Bayer
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | clindamycin phosphate / Generic mfg.
New P4 trial: Clindamycin to Reduce Preterm Birth in a Low Resource Setting (clinicaltrials.gov) - Feb 26, 2013
P4, N=1726, Recruiting, Sponsor: Christiana Care Health Services
- Enrollment open: Surgical Success After Laparoscopic vs Abdominal Hysterectomy (clinicaltrials.gov) - Feb 26, 2013
P4, N=75, Recruiting, Sponsor: University of Texas Southwestern Medical Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- IMNN-001 / Imunon
Trial termination: Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer (clinicaltrials.gov) - Feb 26, 2013
P1, N=18, Terminated, Sponsor: EGEN, Inc.
Not yet recruiting --> Recruiting Completed --> Terminated; Sponsor decided to terminate the study early so they could begin a second dose-escalation study of EGEN-001 in combination with standard chemotherapy.
- cefepime hydrochloride / Generic mfg.
Trial completion: Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia (clinicaltrials.gov) - Feb 26, 2013
P1, N=70, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
Completed --> Terminated; Sponsor decided to terminate the study early so they could begin a second dose-escalation study of EGEN-001 in combination with standard chemotherapy. Active, not recruiting --> Completed
- Enrollment change: Use of Sterile Water Feeds for Treatment of Hypernatremia in Extremely Low Birth Weight Infants (clinicaltrials.gov) - Feb 25, 2013
P=N/A, N=19, Completed, Sponsor: Case Western Reserve University
Active, not recruiting --> Completed N=39 --> 19
- Trial completion: Use of Sterile Water Feeds for Treatment of Hypernatremia in Extremely Low Birth Weight Infants (clinicaltrials.gov) - Feb 25, 2013
P=N/A, N=19, Completed, Sponsor: Case Western Reserve University
N=39 --> 19 Not yet recruiting --> Completed
- | New P4 trial: Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials (clinicaltrials.gov) - Feb 24, 2013
P4, N=1303, Completed, Sponsor: Istanbul Bakirkoy Maternity and Children Diseases Hospital
- || New P2/3 trial: Oestradiol Pre-treatment in an Ultrashort Flare GnRH Agonist/GnRH Antagonist Protocol in Poor Responders Undergoing IVF (clinicaltrials.gov) - Feb 24, 2013
P2/3, N=70, Recruiting, Sponsor: National and Kapodistrian University of Athens
- | morphine sulphate / Generic mfg., ropivacaine / Generic mfg.
Trial completion, Surgery: Intraperitoneal Ropivacaine Nebulization for Pain Control After Gynecologic Laparoscopic Surgery (clinicaltrials.gov) - Feb 21, 2013
P3, N=140, Completed, Sponsor: San Gerardo Hospital
Not yet recruiting --> Completed Recruiting --> Completed
- |||| Avastin (bevacizumab) / Roche
Enrollment open: BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer (clinicaltrials.gov) - Feb 21, 2013
P2, N=56, Recruiting, Sponsor: AA Secord
Recruiting --> Completed Not yet recruiting --> Recruiting
- Clinical: Vitamin D for the Treatment of Women With Polycystic Ovary Syndrome (PCOS) (clinicaltrials.gov) - Feb 20, 2013
P1/2, N=28, Recruiting, Sponsor: Milton S. Hershey Medical Center
Not yet recruiting --> Recruiting Completed --> Recruiting
- Enrollment closed, HEOR: Pilot Program to Personalize Care & Improve Quality of Life for Women With Ovarian Cancer (clinicaltrials.gov) - Feb 19, 2013
P=N/A, N=28, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Completed --> Recruiting Recruiting --> Active, not recruiting
- thyroxine / Generic mfg.
Enrollment open: Selenium Supplementation in Pregnancy (clinicaltrials.gov) - Feb 18, 2013
P4, N=150, Recruiting, Sponsor: University of Roma La Sapienza
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Nutropin AQ (somatropin) / Ipsen, Roche
Trial withdrawal: Low Dose Growth Hormone in Obese PCOS Women (clinicaltrials.gov) - Feb 17, 2013
P=N/A, N=0, Withdrawn, Sponsor: Oregon Health and Science University
Not yet recruiting --> Recruiting Recruiting --> Withdrawn
- Nutropin AQ (somatropin) / Ipsen, Roche
Trial initiation date: Low Dose Growth Hormone in Obese PCOS Women (clinicaltrials.gov) - Feb 17, 2013
P=N/A, N=0, Withdrawn, Sponsor: Oregon Health and Science University
Recruiting --> Withdrawn Initiation date: May 2008 --> Oct 2010
- Nutropin AQ (somatropin) / Ipsen, Roche
Enrollment change: Low Dose Growth Hormone in Obese PCOS Women (clinicaltrials.gov) - Feb 17, 2013
P=N/A, N=0, Withdrawn, Sponsor: Oregon Health and Science University
Initiation date: May 2008 --> Oct 2010 N=12 --> 0
- Trial termination: Psychosocial Benefits of Exercise in Endometrial Cancer Survivors (clinicaltrials.gov) - Feb 17, 2013
P1, N=2, Terminated, Sponsor: Southern Illinois University
N=12 --> 0 Recruiting --> Terminated; Terminated due to lack of funding required to continue the study.
- Enrollment change: Psychosocial Benefits of Exercise in Endometrial Cancer Survivors (clinicaltrials.gov) - Feb 17, 2013
P1, N=2, Terminated, Sponsor: Southern Illinois University
Recruiting --> Terminated; Terminated due to lack of funding required to continue the study. N=24 --> 2
- Cetrotide (cetrorelix) / EMD Serono
Enrollment change: Use of Antagonist Versus Agonist GnRH in Oocyte Recipient Endometrium Preparation (clinicaltrials.gov) - Feb 13, 2013
P4, N=570, Completed, Sponsor: Instituto Valenciano de Infertilidad, Spain
N=24 --> 2 N=400 --> 570
- | New P4 trial: Surgical Success After Laparoscopic vs Abdominal Hysterectomy (clinicaltrials.gov) - Feb 13, 2013
P4, N=75, Recruiting, Sponsor: University of Texas Southwestern Medical Center
- clomifene citrate / Generic mfg.
New P4 trial, Preclinical: CLOFA: Impact of Clomiphene Citrate Administration During the Early Luteal Phase on Endocrine Profile in IVF Cycles (clinicaltrials.gov) - Feb 13, 2013
P4, N=10, Completed, Sponsor: Fundació Privada Eugin
- || Biomarker, New P3 trial: Evaluation of Anti-mullerian Hormone(AMH) Levels as a Predictive Factor of Response to Weight Loss Treatment in Obese Infertile Women With Poly Cystic Ovary(PCOS) (clinicaltrials.gov) - Feb 13, 2013
P3, N=60, Recruiting, Sponsor: Royan Institute
- New P1/2 trial: Effect of Pre-operative Depo Medroxyprogesterone Acetate on Serum Anti-mullerian Hormone Level After Laparoscopic Ovarian Cystectomy of Endometriomas (clinicaltrials.gov) - Feb 13, 2013
P1/2, N=40, Completed, Sponsor: Mahidol University
- cisplatin / Generic mfg.
New P1/2 trial, Metastases: DEPICT: Intensity-modulated Radiotherapy for Locally Advanced Cervical Cancer (clinicaltrials.gov) - Feb 13, 2013
P1/2, N=44, Recruiting, Sponsor: Queen Mary University of London
- Enrollment closed: Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy (clinicaltrials.gov) - Feb 11, 2013
P=N/A, N=45, Active, not recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
N=400 --> 570 Recruiting --> Active, not recruiting
- Trial completion: PUSHOCTII: Study of the Diagnostic Efficacy of "Real Time" Niris 1300e Optical Coherence Tomography (OCT) Imaging System in the Management of Pre-invasive and Invasive Neoplasia of the Uterine Cervix (clinicaltrials.gov) - Feb 11, 2013
P=N/A, N=100, Completed, Sponsor: Preventive Oncology International, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment change: The Effect of Stress on DNA Integrity and the Effect of Cognitive Behavioral Therapy on Stress and Infertility in Women (clinicaltrials.gov) - Feb 10, 2013
P=N/A, N=70, Completed, Sponsor: Soroka University Medical Center
Active, not recruiting --> Completed N=120 --> 70
- || Enrollment closed: Anterior Pelvic Prolapse Reconstruction With TiLOOP® Total 6 (clinicaltrials.gov) - Feb 10, 2013
P=N/A, N=290, Active, not recruiting, Sponsor: pfm medical ag
N=120 --> 70 Recruiting --> Active, not recruiting
- Trial completion: The Effect of Stress on DNA Integrity and the Effect of Cognitive Behavioral Therapy on Stress and Infertility in Women (clinicaltrials.gov) - Feb 10, 2013
P=N/A, N=70, Completed, Sponsor: Soroka University Medical Center
Recruiting --> Active, not recruiting Not yet recruiting --> Completed
- Cytovene (ganciclovir) / Roche
Trial completion, Viral vector: A Study of an Infectivity Enhanced Suicide Gene Expressing Adenovirus for Ovarian Cancer in Patients With Recurrent Ovarian and Other Selected Gynecologic Cancers (clinicaltrials.gov) - Feb 10, 2013
P1, N=11, Completed, Sponsor: University of Alabama at Birmingham
Not yet recruiting --> Completed Active, not recruiting --> Completed
- doxycycline / Generic mfg.
New P3 trial: MI-PCOS: Effect of a Commonly Used Antibiotic, Doxycycline, in Women With Polycystic Ovarian Syndrome (clinicaltrials.gov) - Feb 7, 2013
P3, N=40, Recruiting, Sponsor: University of Rochester
- carboplatin / Generic mfg., cyclophosphamide / Generic mfg., amifostine / Generic mfg.
Enrollment change: Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer (clinicaltrials.gov) - Feb 7, 2013
P1/2, N=11, Completed, Sponsor: University of Chicago
Active, not recruiting --> Completed N=28 --> 11
- ||| Avastin (bevacizumab) / Roche
Clinical: BOVARI: A Non-Interventional Study of Avastin (Bevacizumab) as Front-Line Treatment in Patients With Ovarian Cancer (clinicaltrials.gov) - Feb 7, 2013
P=N/A, N=100, Recruiting, Sponsor: Hoffmann-La Roche
- carboplatin / Generic mfg., cyclophosphamide / Generic mfg., amifostine / Generic mfg.
Trial completion: Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer (clinicaltrials.gov) - Feb 7, 2013
P1/2, N=11, Completed, Sponsor: University of Chicago
N=28 --> 11 Active, not recruiting --> Completed
- Enrollment change: Exercise and Healthy Diet or Standard Care in Patients in Remission From Stage I or Stage II Endometrial Cancer (clinicaltrials.gov) - Feb 6, 2013
P=N/A, N=74, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed N=126 --> 74
- Enrollment closed: EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov) - Feb 6, 2013
P2, N=56, Active, not recruiting, Sponsor: Gynecologic Oncology Group
N=126 --> 74 Recruiting --> Active, not recruiting
- Trial completion: Exercise and Healthy Diet or Standard Care in Patients in Remission From Stage I or Stage II Endometrial Cancer (clinicaltrials.gov) - Feb 6, 2013
P=N/A, N=74, Completed, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Completed